Diabetes Home > Generic Invokana
Patents are currently in place that prevent companies from making a generic version of Invokana (canagliflozin). After the first patent expires in July 2024, however, this situation may change. Although canagliflozin is often referred to as the "generic name" for Invokana, it is simply the active ingredient in this product and not a generic version of it.
Invokana® (canagliflozin) is a prescription medication approved for treating type 2 diabetes. It is the first in a class of diabetes medications known as sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors).
Invokana is manufactured by Janssen Pharmaceuticals, Inc. At this time, generic Invokana is not available.
The first patent for Invokana is set to expire in July 2024. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This includes such things as lawsuits or other patents for new Invokana uses. Once the patents expire, there may be several companies that manufacture a generic Invokana drug.
No -- canagliflozin is the active ingredient in Invokana, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.